Selected article for: "China Wuhan outbreak and respiratory illness"
Author: Baghchechi, Mohsen; Jaipaul, Navin; Jacob, Sharon E.
Title: The rise and evolution of COVID-19
  • Cord-id: yrylqim6
  • Document date: 2020_6_26
    • ID: yrylqim6
    Snippet: Abstract Coronaviridae (CoV) is a large family of zoonotic viruses linked to a range of diseases from the common cold to the severe SARS-CoV and MERS-CoV epidemics. In 2019, a novel virus emerged from Wuhan, China characterized by a marked worldwide outbreak of respiratory illness. Prevention and containment became the prioritized intervention against COVID-19, coupled with a continued search for hallmarks of the disease which would allow early detection and provide insight to management and tri
    Document: Abstract Coronaviridae (CoV) is a large family of zoonotic viruses linked to a range of diseases from the common cold to the severe SARS-CoV and MERS-CoV epidemics. In 2019, a novel virus emerged from Wuhan, China characterized by a marked worldwide outbreak of respiratory illness. Prevention and containment became the prioritized intervention against COVID-19, coupled with a continued search for hallmarks of the disease which would allow early detection and provide insight to management and triage. Cutaneous findings associated with COVID include diffuse maculopapular rashes, livedo reticularis, and acro-ischemic ‘COVID toes’. These skin findings occurred anywhere from days before respiratory symptom onset to weeks after recovery, and predominantly in the child and adolescent population. The role of dermatologists can be expanded during this COVID-19 pandemic to help identify disease through cutaneous presentations.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and additional patient: 1
    • action mechanism and liver injury: 1, 2, 3, 4, 5
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active infection and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • active infection and adaptive immunity: 1, 2, 3
    • active infection and adolescent population: 1
    • active infection and liver injury: 1
    • active infection and lopinavir ritonavir: 1, 2
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and additional patient: 1, 2
    • acute ards respiratory distress syndrome and adolescent child: 1
    • acute ards respiratory distress syndrome and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immunity and liver injury: 1
    • adaptive immunity and lopinavir ritonavir: 1, 2
    • additional patient and lopinavir ritonavir: 1